Transient abnormal myelopoiesis complicated by tumor lysis syndrome

Abe, Yoshifusa; Mizuno, Katsumi; Hara, Hiroshi; Mizutani, Kayo; Okimoto, Yuri

doi:10.1111/j.1442-200x.2006.02237.x-i1

Cited by 8 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…But in the presence of one or more LTS, intervention like low-dose cytosine arabinoside is advised. 12 15,16 Kato et al, reported a case of a baby with DS who developed TLS as a result of TL-DS and was successfully treated with allopurinol and diuretics. 15 The risk factors for mortality in TL-DS are hyperleukocytosis, hepatic dysfunction, effusions, prematurity, low birth weight and renal failure.…”

Section: Discussionmentioning

confidence: 99%

Transient leukaemia of Down syndrome in a neonate: case report

Bhaisara

Korday

Wade

et al. 2019

Int J Contemp Pediatr

View full text Add to dashboard Cite

A 30 year old elderly primigravida, married since 13 years with no history of abortions and consanguinity, delivered vaginally a 1.6 kg, 32 week preterm female baby. Baby had normal APGAR score at birth and was admitted in NICU for prematurity and low birth weight. Our patient had characteristic DS facies with bilateral pre-auricular tags without organomegaly ( Figure 1). Investigations done on the 3rd day of life revealed a total ABSTRACT Transient leukemia of Down syndrome(TL-DS) or transient myeloproliferative disorder (TMD) or transient abnormal myelopoiesis (TAM) is a hematologic abnormality characterized by an uncontrolled proliferation of myeloblasts in peripheral blood and bone marrow which characteristically affects newborns and babies with Down syndrome. Children with Down syndrome (Trisomy 21) have a unique predisposition to develop myeloid leukemia of Down syndrome(ML-DS). In majority of cases of TL-DS, the GATA1 mutant clone goes into spontaneous remission without the need for chemotherapy. However, 10-20 % of neonates with TL-DS and silent TL-DS subsequently develop ML-DS in the first 5 years of life due to additional oncogenic mutations acquired by the persistent GATA1 mutant cells. We present here, one such case of Down syndrome with TL-DS in a neonate.

show abstract

Section: Discussionmentioning

confidence: 99%

Transient leukaemia of Down syndrome in a neonate: case report

Bhaisara

Korday

Wade

et al. 2019

Int J Contemp Pediatr

View full text Add to dashboard Cite

show abstract

“…15 Bu olguların tedavisinde diüretikler, allopurinol ve rasburikaz gibi ajanlar kullanılabilir. Olgumuzda ise kemoterapiye bağlı yan etki göz-lenmedi.…”

Section: Discussionunclassified

Transient Myeloproliferative Disease Treated with Low Dose Cytarabine in a Newborn with Down Syndrome: Case Report

Melekoğlu¹,

Taviloğlu²,

Burulday³

et al. 2015

Turkiye Klinikleri J Case Rep

View full text Add to dashboard Cite

“…Besides the afore-mentioned effects, decreasing the blast cell count by exchange transfusion reduces the risk of tumor lysis syndrome during subsequent chemotherapy. 10 Although the reports of exchange transfusion appear to be limited, it should be considered in acute period as first line therapy with rapid decline in blast cells. 8 Low-dose Ara-C treatment is recommended for patients who have TAM with clinical impairment.…”

Section: Discussionmentioning

confidence: 99%

Improving Circulatory Disturbance in Transient Abnormal Myelopoiesis

Koga

Miyako²,

Suga³

et al. 2012

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

Transient abnormal myelopoiesis (TAM) in neonates with Down syndrome (DS) is characterized by circulating blast cells in the blood. TAM usually resolves spontaneously, but several studies have associated this condition with early death, focusing on the development of effective treatments. We report the case of a neonate with DS who had TAM and novel GATA1 mutation. Although the patient eventually died of hepatic failure, exchange blood transfusion and low-dose cytarabine treatment dramatically improved pulmonary hypertension and acute renal failure refractory to conventional therapy. Such a blast-reducing approach might be useful for improving circulatory disturbances in neonates with DS and TAM.

show abstract

Transient abnormal myelopoiesis complicated by tumor lysis syndrome

Cited by 8 publications

References 11 publications

Transient leukaemia of Down syndrome in a neonate: case report

Transient leukaemia of Down syndrome in a neonate: case report

Transient Myeloproliferative Disease Treated with Low Dose Cytarabine in a Newborn with Down Syndrome: Case Report

Improving Circulatory Disturbance in Transient Abnormal Myelopoiesis

Contact Info

Product

Resources

About